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Development of Validated Assays 
for Measuring the Human 
Antibody Response to 
Polysaccharide Conjugate 
Vaccines
2Conjugate vaccines
• Haemophilus influenzae type b (Hib)
• Neisseria meningitidis (Men)
• Streptococcus pneumoniae (Pnc)
3The capsules
• For all, antibody to capsule has been 
proven protective via complement 
mediated mechanisms
? Bactericidal activity (lysis)
? Opsonizing for phagocytosis
4Functional activity of antibodies
• Serum bactericidal activity (SBA)
? The ability of antibodies to mediate killing of bacteria in the 
presence of complement 
= antibody and complement mediated lysis
• Serum opsonophagocytic activity (OPA)
? The ability of antibodies to mediate opsonization of bacteria 
for phagocytosis by phagocytosing cells (PMNL, HL-60) in 
the presence of complement 
= antibody and complement mediated phagocytosis
• OBS! Animal experiments do not (always) correlate 
with the properties of the conjugate and 
polysaccharide vaccines humans
5Antibody concentration
? For all, antibody concentration can be measured 
by radioimmunoassay (RIA) or enzyme 
immunoassay (EIA)
6Immunological memory
• Important for long term protection together 
with sustaining antibody concentrations
• Challenge of memory B cells with a 
polysaccharide or conjugate vaccine → 
measure antibodies by EIA
• Determination of antibody avidity maturation
7Assays need to be
• Carefully validated
• Standardized and with good QC
• Give comparable results in different 
laboratories
? Reagents (e.g. EIA antigens and reagents, 
complement source)  
? Reference and QC materials
? Strains
Hib conjugate vaccines
9Four different Hib conjugate vaccines
PRP-D HbOC PRP-OMPC PRP-T
Trade name
ProHIBit HibTiter PedvaxHIB
ActHib, 
Hiberix
Manu
facturer
Wyeth Merck sanofi 
pasteur,
GSK
Carrier Diphtheria
toxoid (D)
Mutant 
diphtheria
Toxin 
(CRM)
Men OMP 
complex
Tetanus 
toxoid (T)
PS μg 25 (sized) 10 (OS) 7.5 (native) 10 (native)
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WHO Recommendation
http://www.who.int/biologicals/publications/meetings/areas/vaccines/en/
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Evaluation criteria
? Primary endpoint: antibody concentration post 
primary vaccination series 
• Thresholds 0.15 and 1.0 µg/ml
? Functional activity of antibodies measured by SBA 
(or OPA)
? Immunologic memory
• Booster response
• Avidity
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Challenge 1
• Radioimmunoassay (RIA) used in 1970-80’s 
→ concentrations associated with protection
• Enzyme immunoassays (EIA) replaced RIA
? Interlaboratory comparisons
? Different protocols
? Should give equivalent results to RIA
• Reference serum lot 1983 and QC sera from 
US FDA 
• EIA antigen (HbOHA) from NIBSC, UK
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Search of correlates for Hib PS vaccines
Käyhty ea, JID 1983
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Challenge 1
• Radioimmunoassay (RIA) used in 1970-80’s -
> concentrations associated with protection
• Enzyme immunoassays (EIA) replaced RIA
? Interlaboratory comparisons
? Different protocols
? Should give equivalent results to RIA
• Reference serum lot 1983 and QC sera from 
US FDA 
• EIA antigen (HbOHA) from NIBSC, UK
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Challenge 2.
Continuing need of immunogenicity evaluation
• Several Hib conjugate vaccines licensed and in use in 
developed and developing countries
• Licensure of new vaccines based on immunogenicity 
data and safety
• Component of combination vaccines
• Schedules
• Use in resource poor countries with high risk of Hib 
disease
• Risk groups among adults
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Useful address
http://www.vaccine.uab.edu/
Information on hemophilus and 
pneumococcal assays
Meningococcal conjugate 
vaccines
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Meningococcal conjugate vaccines
• MenC
? carriers: mutant diphtheria toxin (CRM) , tetanus toxoid  (T) 
? used widely in Europe
• MenACW135Y
? Carrier: diphtheria toxoid (D)
? CRM conjugate in clinical trials
? Used in USA for adolescents; clinical trials in infants 
ongoing
• MenA
? Planned to be used in African meningitis belt
? The Meningitis Vaccine Project 
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World Health Organization
WHO Technical Report Series, No. 926, 2004
Recommendations for the production and control 
of group C meningococcal conjugate vaccines
APPENDIX 1 
Evaluation of the immunogenicity of group C 
meningococcal conjugate vaccines
WHO/BS/06.2041- 2006 Final
RECOMMENDATIONS TO ASSURE THE QUALITY, 
SAFETY AND EFFICACY OF GROUP A 
MENINGOCOCCAL CONJUGATE VACCINES
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WHO Expert Committee:
Thresholds associated with protection for 
MenC CVs:
• SBA is a gold standard
? Baby rabbit complement: titer of ≥8 (rSBA)
? Additional indicators: ≥4- fold rise or a titer of ≥4 
with human complement (hSBA)
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Meningococcal SBA in cases and controls
Sera of cases
Sera of healthy 
controls
Homologous strain 3/54 (5.6%) 444/540 (82.2%)
Goldschneider I et al. J Exp Med 1969; 129: 1307–26
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Challenge 1. 
Human or rabbit complement?
• Original Goldschneider study used human 
complement (hSBA) 
• Difficult to get and standardize
• Baby rabbit complement commercially available... 
but gives higher SBA titers
• UK experience with rSBA and Menc conjugates:
? rSBA titer of ≥1:8 in immunized infants and 
children correlates with effectiveness in post 
licensure surveillance (Andrews et al. Clin Diag 
Lab Immunol 2003) 
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MenC disease and prevalence of rSBA
Trotter et al. Vaccine 2003
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Challenge 2.
Serogroups A, W135, Y
• Are criteria set up for MenC valid for other 
serogroups?
• Which strains are the relevant to be used in 
SBA?
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Challenge 3:
EIA or comparable assays for isotype specific 
antibody concentrations
• Concentration associated with protection not 
determined
• OBS! Should correlate with SBA 
• To increase correlation use
? Pure polysaccharide antigens
? Derivatized polysaccahride antigens
? Chaotropic agents (thiocyanate) to detach antibodies of 
low affinity (assumed to be not protective)
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Reagents for EIA available
NIBSC, Potters Bar, UK
• Polysaccharides
• Reference serum
• Methylated serum albumin for enhancing the 
binding of PS to solid phase
Pneumococcal conjugate 
vaccines
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Pneumococcal conjugate vaccines
• PncCRM; Wyeth.
? Carrier: mutant diphtheria toxin, CRM197  
? At present 7-valent vaccine lisenced (Prevenar, Prevnar)
? 13-valent vaccine in clinical trials
• PncPD; GSK
? Carrier: H. influenzae Protein D
? 11-valent vaccine tested in clinical efficacy trials
? 10-valent mixed carrier vaccine filed for licensure
• PncOMPC; Merck
? Carrier: meningococcal outer membrane protein complex
? 7-valent vaccine tested in clinical efficacy trial
? Company has stopped the development
• PncDT, sanofi pasteur
? Carriers: diphtheria and tetanus toxoids
? 11-valent vaccine tested in clinical efficacy trial
? Company has stopped the development
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World Health Organization
WHO Technical Report Series, No. 927, 2005
Annex 2
Recommendations for the production and control 
of pneumococcal conjugate vaccines
Appendix
Serological criteria for evaluation and licensure of
new pneumococcal conjugate vaccine formulations
for use in infants
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Pneumococcal conjugate vaccines
• Acceptance of nwe vaccines, schedules, 
combinations, based mainly on immunological 
studies
• Primary threshold for all serotypes = % subjects 
with 0.35 µg/ml of antibody measured by EIA1
• Secondary thresholds
? Demonstration of functional activity of 
antibodies by testing OPA
? Demonstration of immunological memory
1http://www.who.int/biologicals/publications/meetings/areas/vaccines/en/
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Challenge 1:
• Noninferiority to a licensed vaccine 
• Primary threshold for all serotypes = % 
subjects with 0.35 µg/ml of antibody 
measured by EIA
• 0.35 µg/ml threshold determined with non-22F 
EIA
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http://www.vaccine.uab.edu/
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Problems with EIAs
• The commercial antigens are not pure
• To gain type specificity absorptions with 
cell wall polysaccharide (CPS) and 22F PS 
needed
• The effects of extra steps seem to vary in 
different labs
• What to do when 22F is included in the Pnc 
conjugate vaccine
• Danish approach: CPS2 from 22F strain
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Antibody to type 11A
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Soininen et al. Clin Diag Lab Imm 2001 
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Absorption with CPS or with CPS+22F
Concepcion & Frasch, Clin Diag Lab Imm 2001
Serum from an unimmunized adult 
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Correlation of EIA and OPA
R=0.66 R=0.92
Concepcion & Frasch, Clin Diag Lab Imm 2001
Serum samples from adults, type 4
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Problems with EIAs
• The commercial antigens are not pure
• To gain type specificity absorptions with Cell 
wall polysaccharide (CPS) and 22F PS 
needed
• The effects of extra steps seem to vary in 
different labs
• What to do when 22F is included in the Pnc 
conjugate vaccine
• Danish approach: CPS2 from 22F strain
38
Reagents for EIA available
• Polysaccharides form ATCC
• CPS from SSI, Denmark
• Reference serum 89S from US FDA
• QC sera from NIBSC
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Challenge 2:
Opsonophagocytosis assay for demonstration 
of functionality of antibodies
• Validated by several groups
• Interlaboratory standardization and 
harmonization in process 
• Strains, effector cells (HL60), detection, 
calculation of results
• High throughput assays needed
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Challenge 3:
• Development of immunoassays that would 
predict protection against other than invasive 
disease
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Challenges for all three
• The significance of demonstration of increase 
in avidity 
• Standardization of the assays for measuring 
avidity
• Reliable and robust multiplexed assays for 
measuring concentration and functional 
activity of antibodies.  
? Should be able to be transfered easily to other 
labs
